Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,263 across all filing types
Latest filing 2022-05-27 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
In terms of SEBI's Circular No. CIR/CFD/CMD1/27/2019 dated February 8, 2019, we furnish herewith the Secretarial Compliance Report, for the year ended March 31, 2022.
Regulatory Filings Classification · 95% confidence The document is titled 'Secretarial Compliance Report' for the year ended March 31, 2022, and is addressed to stock exchanges (BSE and NSE). It references compliance with SEBI regulations and lists various SEBI regulations examined. The document is a compliance certification by a practicing company secretary, confirming adherence to regulatory requirements and noting no deviations or violations. It does not contain financial statements or detailed financial analysis but is a regulatory compliance attestation. The document length is about 5,199 characters, which is relatively short and consistent with a compliance report rather than a full annual or interim report. Given these characteristics, the document fits best under Regulatory Filings (RNS), as it is a regulatory compliance report and certification rather than a financial report or announcement of a report publication.
2022-05-27 English
AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 26, 2022, inter alia, has recommended Final Dividend of Rs. 8/- per equity ....
Regulatory Filings
2022-05-26 English
Financial Result Updates
Regulatory Filings
2022-05-26 English
The Board of Directors of the Company at their meeting held today i.e., May 26, 2022, has inter-alia: 1. Approved the Audited Financial Results of the Company for the quarter and ....
Regulatory Filings
2022-05-26 English
Loss of share certificate
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates by shareholders. It references compliance with SEBI Listing Obligations and Disclosure Requirements, specifically Regulation 39(3), which pertains to share certificate loss and reissuance. The content is an announcement about the loss and the intention to issue duplicate certificates, not a financial report, management discussion, or any other detailed corporate filing. The document length is short (1797 characters), and it is clearly an announcement related to share certificates. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory disclosure that does not fit other specific categories like share issue or director dealings.
2022-05-25 English
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, specifically Regulation 39(3), which pertains to share certificate loss and replacement procedures. The content is an announcement of an event (loss of share certificates) and the company's intention to issue duplicate certificates upon completion of formalities. The document is short (1797 characters) and does not contain financial data, management discussion, or detailed report content. It is not a financial report, earnings release, or management report. It is also not a regulatory filing in the sense of officer certifications or compliance documents but rather a specific notification related to share certificates. This type of document fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like Director's Dealing or Share Issue/Capital Change, since it concerns lost certificates and duplicate issuance rather than new share issuance or insider transactions.
2022-05-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.